Hemab Therapeutics Holdings, Inc. (COAG) Stock Forecast
COAG analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $62.67 average of analyst targets
- Upside to target
- +108.4% from the latest close
- Next earnings
- November 10, 2026 EPS estimate $-0.50
- 52-week range
- $18.00 – $54.94
COAG analyst ratings
6 analystsNumber of analysts at each rating.
COAG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
COAG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.55 | −$0.41 | — | — | 5 |
| Current fiscal year (2026) | −$3.11 | −$3.23 | −$2.77 | — | — | 5 |
| Next fiscal year (2027) | −$2.55 | −$2.81 | −$2.30 | −$3.11 | +18.1% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
COAG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
COAG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
COAG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.49 | −$0.51 | −$0.51 | −$0.51 | −$0.52 | +5.9% | 0 up · 2 down |
| Current fiscal year (2026) | −$3.06 | −$3.10 | −$3.10 | −$3.10 | −$3.11 | +1.5% | 1 up · 2 down |
| Next fiscal year (2027) | −$2.51 | −$2.54 | −$2.54 | −$2.54 | −$2.55 | +1.3% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
COAG earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; COAG beat in 0 of 1.
What analysts expect from COAG
6 analysts cover Hemab Therapeutics; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $62.67, 108.4% above the latest close of $30.07. Analysts expect earnings of −$3.11 per share for 2026. For 2027 the average estimate is −$2.55 per share. Hemab Therapeutics beat the EPS estimate in 0 of the last 1 quarters.
Related: COAG income statement, COAG key metrics, COAG chart. See the COAG stock overview for the latest quote and news.
COAG forecast FAQ
What is Hemab Therapeutics's price target?
The average analyst price target for Hemab Therapeutics is $62.67, 108.4% above the latest close of $30.07.
Is Hemab Therapeutics a buy, hold or sell?
Of 6 analysts covering Hemab Therapeutics, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Hemab Therapeutics's EPS forecast?
Analysts forecast −$3.11 per share for 2026 (range −$3.23 to −$2.77); for 2027 the estimate is −$2.55.
When does Hemab Therapeutics report earnings?
Hemab Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 10, 2026; the EPS estimate is $-0.50.
Does Hemab Therapeutics usually beat earnings estimates?
Hemab Therapeutics reported EPS at or above the analyst estimate in 0 of the last 1 quarters.